Literature DB >> 24458500

Clinical characteristics and outcomes of patients with pleural infections due to Stenotrophomonas maltophilia at a medical center in Taiwan, 2004-2012.

M-R Lee1, H-C Wang, C-Y Yang, C-K Lin, H-Y Kuo, J-C Ko, W-H Sheng, L-N Lee, C-J Yu, P-R Hsueh.   

Abstract

Stenotrophomonas maltophilia can cause various clinical diseases; however, pleural infections due to S. maltophilia are rare. We evaluated the clinical characteristics and outcomes of patients with pleural infections (complicated parapneumonic effusion or empyema) due to S. maltophilia who were treated at a medical center in Taiwan from 2004 to 2012. During the study period, 40 patients were treated for pleural infections due to S. maltophilia. The incidence of S. maltophilia pleural infections ranged from 2.66 per 1,000,000 patient-days in 2009 to 12.44 per 1,000,000 patient-days in 2011. Most of the patients with S. maltophilia pleural infections were immunocompromised male adults and all of the infections were acquired in healthcare settings. The majority of patients had polymicrobial pleural infections (n = 31, 77.5 %) and the most common pathogen was Pseudomonas aeruginosa (n = 12). The causes of pleural infections due to S. maltophilia were pneumonia due to S. maltophilia in two patients (5 %), post-surgical/tube thoracostomy in 26 (65 %) patients, and fistula (bronchopleural, esophagopleural and biliopleural) in 12 (30 %) patients. The 14-day and 30-day mortality rates were 32.5 % and 42.5 %, respectively. Pleural infections due to S. maltophilia are most commonly the result of surgical procedures, thoracostomy, and underlying fistulas. These infections are associated with a high mortality rate, especially among immunocompromised patients.

Entities:  

Mesh:

Year:  2014        PMID: 24458500     DOI: 10.1007/s10096-014-2060-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  37 in total

Review 1.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

2.  [Analysis of clinical characteristics and drug sensitivity tests of lower respiratory tract infection by Xanthomonas maltophilia].

Authors:  Z Liu; Z Zhao; J Xiong
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  1999-04

Review 3.  Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review.

Authors:  Matthew E Falagas; Politimi-Eleni Valkimadi; Yu-Tsung Huang; Dimitrios K Matthaiou; Po-Ren Hsueh
Journal:  J Antimicrob Chemother       Date:  2008-07-28       Impact factor: 5.790

Review 4.  Stenotrophomonas maltophilia: an unusual cause of biliary sepsis.

Authors:  K A Papadakis; S E Vartivarian; M E Vassilaki; E J Anaissie
Journal:  Clin Infect Dis       Date:  1995-10       Impact factor: 9.079

5.  Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients.

Authors:  Laurence Armand-Lefèvre; Cécile Angebault; François Barbier; Emilie Hamelet; Gilles Defrance; Etienne Ruppé; Régis Bronchard; Raphaël Lepeule; Jean-Christophe Lucet; Assiya El Mniai; Michel Wolff; Philippe Montravers; Patrick Plésiat; Antoine Andremont
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

6.  Stenotrophomonas maltophilia bloodstream infection: comparison between community-onset and hospital-acquired infections.

Authors:  Ya-Ting Chang; Chun-Yu Lin; Po-Liang Lu; Chung-Chih Lai; Tun-Chieh Chen; Chi-Yu Chen; Deng-Chyang Wu; Tzu-Pin Wang; Chiu-Mei Lin; Wei-Ru Lin; Yen-Hsu Chen
Journal:  J Microbiol Immunol Infect       Date:  2012-10-02       Impact factor: 4.399

7.  Stenotrophomonas maltophilia: an emerging opportunist human pathogen.

Authors:  W John Looney; Masashi Narita; Kathrin Mühlemann
Journal:  Lancet Infect Dis       Date:  2009-05       Impact factor: 25.071

Review 8.  Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature.

Authors:  Matthew E Falagas; Antonia C Kastoris; Evridiki K Vouloumanou; Petros I Rafailidis; Anastasios M Kapaskelis; George Dimopoulos
Journal:  Future Microbiol       Date:  2009-11       Impact factor: 3.165

Review 9.  Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer.

Authors:  Amar Safdar; Kenneth V Rolston
Journal:  Clin Infect Dis       Date:  2007-12-15       Impact factor: 9.079

10.  The changing pathogens of complicated parapneumonic effusions or empyemas in a medical intensive care unit.

Authors:  Chih-Yen Tu; Wu-Huei Hsu; Te-Chun Hsia; Hung-Jen Chen; Kuo-Liang Chiu; Liang-Wen Hang; Chuen-Ming Shih
Journal:  Intensive Care Med       Date:  2006-02-15       Impact factor: 17.440

View more
  6 in total

1.  Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study.

Authors:  Philippe Guerci; Hugo Bellut; Mokhtar Mokhtari; Julie Gaudefroy; Nicolas Mongardon; Claire Charpentier; Guillaume Louis; Parvine Tashk; Clément Dubost; Stanislas Ledochowski; Antoine Kimmoun; Thomas Godet; Julien Pottecher; Jean-Marc Lalot; Emmanuel Novy; David Hajage; Adrien Bouglé
Journal:  Crit Care       Date:  2019-11-21       Impact factor: 9.097

2.  Multiplex bacterial polymerase chain reaction in a cohort of patients with pleural effusion.

Authors:  Léo Franchetti; Desiree M Schumann; Michael Tamm; Kathleen Jahn; Daiana Stolz
Journal:  BMC Infect Dis       Date:  2020-02-01       Impact factor: 3.090

Review 3.  Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.

Authors:  Ya-Ting Chang; Chun-Yu Lin; Yen-Hsu Chen; Po-Ren Hsueh
Journal:  Front Microbiol       Date:  2015-09-02       Impact factor: 5.640

4.  Etiology of parapneumonic effusion and pleural empyema in children. The role of conventional and molecular microbiological tests.

Authors:  Katarzyna Krenke; Ewa Sadowy; Edyta Podsiadły; Waleria Hryniewicz; Urszula Demkow; Marek Kulus
Journal:  Respir Med       Date:  2016-05-10       Impact factor: 3.415

Review 5.  Empiric Treatment in HAP/VAP: "Don't You Want to Take a Leap of Faith?"

Authors:  Khalil Chaïbi; Gauthier Péan de Ponfilly; Laurent Dortet; Jean-Ralph Zahar; Benoît Pilmis
Journal:  Antibiotics (Basel)       Date:  2022-03-08

6.  Stenotrophomonas maltophilia outer membrane protein A induces epithelial cell apoptosis via mitochondrial pathways.

Authors:  Xin Wang; Yan Li; Xueping Tang; Xueyi Shang; Zunquan Zhao; Yongqiang Jiang; Yan Li
Journal:  J Microbiol       Date:  2020-09-02       Impact factor: 3.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.